Dianthin-EGF is an effective tumor targeted toxin in combination with saponins in a xenograft model for colon carcinoma (Q38932565)

7 September 2017

title

Dianthin-EGF is an effective tumor targeted toxin in combination with saponins in a xenograft model for colon carcinoma (English)

1 reference

7 September 2017

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471031%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Benedicta von Mallinckrodt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471031%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Mayank Thakur

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471031%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Roger Gilabert-Oriol

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471031%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Horst Dürkop

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471031%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Winfried Brenner

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471031%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Mathias Lukas

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471031%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Nicola Beindorff

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471031%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Matthias F Melzig

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471031%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Hendrik Fuchs

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471031%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

1 November 2014

1 reference

7 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471031%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471031%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471031%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

2161-2175

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471031%20AND%20SRC:MED&resulttype=core&format=json

Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs

10 June 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Immunotoxins and other conjugates: pre-clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Sex hormones and colorectal cancer: what have we learned so far?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

EGFR and colon cancer: a clinical view.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Comparing antibody and small-molecule therapies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Saponins modulate the intracellular trafficking of protein toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Real time monitoring of the cell viability during treatment with tumor-targeted toxins and saponins using impedance measurement.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Dianthins, ribosome-damaging proteins with anti-viral properties from Dianthus caryophyllus L. (carnation).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Small structural differences of targeted anti-tumor toxins result in strong variation of protein expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Targeted tumor therapy by epidermal growth factor appended toxin and purified saponin: an evaluation of toxicity and therapeutic potential in syngeneic tumor bearing mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Worldwide variations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Production and characterization of a colon cancer-specific immunotoxin based on the fungal ribotoxin α-sarcin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Prediction in rectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Macromolecular interactions of triterpenoids and targeted toxins: role of saponins charge.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

A convenient method for saponin isolation in tumour therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

The toxin component of targeted anti-tumor toxins determines their efficacy increase by saponins.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Ribosome-inactivating proteins depurinate poly(ADP-ribosyl)ated poly(ADP-ribose) polymerase and have transforming activity for 3T3 fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Recommendations on the use of 18F-FDG PET in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.164

21 January 2018

Identifiers

DOI

10.2217/FON.14.164

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471031%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference